Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Vemurafenib |
Indication/Tumor Type | ameloblastoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | ameloblastoma | sensitive | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Zelboraf (vemurafenib) inhibited viability of an ameloblastoma cell line harboring BRAF V600E in culture (PMID: 24859340). | 24859340 |
BRAF V600E | ameloblastoma | sensitive | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Zelboraf (vemurafenib) inhibited viability of ameloblastoma cell lines harboring BRAF V600E in culture (PMID: 35689405). | 35689405 |
PubMed Id | Reference Title | Details |
---|---|---|
(24859340) | Identification of recurrent SMO and BRAF mutations in ameloblastomas. | Full reference... |
(35689405) | New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies. | Full reference... |